GlassScriptPhysician profile
John A Davis
NPI 1104918879
$1,328.07
in general payments reported to CMS, 2019-2025
34 companies · $387 in 2025
The $387 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $221 · 2021: $73.55 · 2022: $230 · 2023: $50.10 · 2024: $207 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $199.17 | 2019-2022 | |
| Globus Medical, INC. | $181.32 | 2021-2025 | Excelsius Gps, Simplify Cervical Artificial Disc, Canopy |
| Abbvie INC. | $79.64 | 2022-2024 | Ubrelvy |
| Ucb, INC. | $79.08 | 2020-2022 | |
| Amgen INC. | $65.47 | 2019-2021 | |
| Providence Medical Technology, INC. | $57.80 | 2024 | |
| Depuy Synthes Sales INC. | $49.87 | 2019-2023 | Fibergraft Bg Morsels |
| Lundbeck LLC | $47.49 | 2024-2025 | Vyepti |
| Stryker Corporation | $42.56 | 2020 | |
| Medtronic, INC. | $38.58 | 2025 | Mazor X System, Unid_pass |
| Grifols USA, LLC | $35.23 | 2025 | Gamunex-C |
| Paratek Pharmaceuticals, INC. | $34.93 | 2022 | |
| Arbor Pharmaceuticals, INC. | $28.04 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $26.49 | 2021-2025 | Austedo Xr |
| Pfizer INC. | $25.14 | 2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $22.30 | 2024 | Vyvgart Hytrulo |
| Sk Life Science, INC. | $21.31 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.23 | 2019 | |
| Saluda Medical Americas, INC. | $20.14 | 2025 | Evoke |
| Merz Pharmaceuticals, LLC | $19.72 | 2025 | Xeomin |
| Takeda Pharmaceuticals U.S.A., INC. | $19.51 | 2025 | Hyqvia |
| Biogen, INC. | $18.94 | 2025 | Vumerity |
| Boston Scientific Corporation | $18.77 | 2024 | |
| Kyowa Kirin, INC. | $18.75 | 2024 | Nourianz |
| Eisai INC. | $18.56 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.53 | 2025 | Wainua |
| Ani Pharmaceuticals, INC. | $18.25 | 2025 | Purified Cortrophin Gel |
| Daiichi Sankyo INC. | $17.58 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $16.55 | 2020 | |
| Alexion Pharmaceuticals, INC. | $15.50 | 2019 | |
| Convatec INC. | $14.89 | 2024 | |
| Sanofi-Aventis U.S. LLC | $13.22 | 2023 | |
| Smith+Nephew, INC. | $11.94 | 2022 | |
| Almatica Pharma LLC | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.